Literature DB >> 19623660

Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3.

Karuppaiyah Selvendiran1, Anna Bratasz, M Lakshmi Kuppusamy, Mia F Tazi, Brian K Rivera, Periannan Kuppusamy.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is activated in a variety of human cancers, including ovarian cancer. The molecular mechanism by which the STAT3 is activated in cancer cells is poorly understood. We observed that human ovarian xenograft tumors (A2780) in mice were severely hypoxic (pO(2) approximately 2 mmHg). We further observed that hypoxic exposure significantly increased the phosphorylation of STAT3 (pSTAT3) at the Tyr705 residue in A2780 cell line. The pSTAT3 (Tyr705) level was highly dependent on cellular oxygenation levels, with a significant increase at <2% O(2), and without any change in the pSTAT3 (Ser727) or total STAT3 levels. The pSTAT3 (Tyr705) elevation following hypoxic exposure could be reversed within 12 hr after returning the cells to normoxia. The increased level of pSTAT3 was partly mediated by increased levels of reactive oxygen species generation in the hypoxic cancer cells. Conventional chemotherapeutic drugs cisplatin and taxol were far less effective in eliminating the hypoxic ovarian cancer cells suggesting a role for pSTAT3 in cellular resistance to chemotherapy. Inhibition of STAT3 by AG490 followed by treatment with cisplatin or taxol resulted in a significant increase in apoptosis suggesting that hypoxia-induced STAT3 activation is responsible for chemoresistance. The results have important clinical implications for the treatment of hypoxic ovarian tumors using STAT3-specific inhibitors. (c) 2009 UICC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19623660      PMCID: PMC2893222          DOI: 10.1002/ijc.24601

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

1.  Phosphorylation and activation of STAT proteins by hypoxia in breast cancer cells.

Authors:  Moon Young Lee; Youn Hee Joung; Eun Joung Lim; Jong-Hwan Park; Sang-Kyu Ye; Taekyu Park; Zheng Zhang; Dong Ki Park; Kwang Jeon Lee; Young Mok Yang
Journal:  Breast       Date:  2005-08-03       Impact factor: 4.380

2.  The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.

Authors:  Daniel G Rosen; Imelda Mercado-Uribe; Gong Yang; Robert C Bast; Hesham M Amin; Raymond Lai; Jinsong Liu
Journal:  Cancer       Date:  2006-12-01       Impact factor: 6.860

3.  Non-invasive measurement of tumor oxygenation using embedded microparticulate EPR spin probe.

Authors:  Govindasamy Ilangovan; Anna Bratasz; Periannan Kuppusamy
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

4.  STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival.

Authors:  Manik Chatterjee; Sarika Jain; Thorsten Stühmer; Mindaugas Andrulis; Ute Ungethüm; Ralf-Jürgen Kuban; Heike Lorentz; Kurt Bommert; Max Topp; Doris Krämer; Hans Konrad Müller-Hermelink; Hermann Einsele; Axel Greiner; Ralf C Bargou
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

5.  Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids.

Authors:  Karuppaiyah Selvendiran; Hironori Koga; Takato Ueno; Takafumi Yoshida; Michiko Maeyama; Takuji Torimura; Hirohisa Yano; Masamichi Kojiro; Michio Sata
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

6.  Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor.

Authors:  Chang Xia; Qiao Meng; Ling-Zhi Liu; Yongyut Rojanasakul; Xin-Ru Wang; Bing-Hua Jiang
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

7.  Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells.

Authors:  Ashutosh K Pathak; Manisha Bhutani; Asha S Nair; Kwang Seok Ahn; Arup Chakraborty; Humam Kadara; Sushovan Guha; Gautam Sethi; Bharat B Aggarwal
Journal:  Mol Cancer Res       Date:  2007-09       Impact factor: 5.852

8.  NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.

Authors:  Karuppaiyah Selvendiran; Anna Bratasz; Liyue Tong; Louis J Ignarro; Periannan Kuppusamy
Journal:  Cell Cycle       Date:  2007-09-28       Impact factor: 4.534

Review 9.  Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs.

Authors:  Lidija Klampfer
Journal:  Curr Cancer Drug Targets       Date:  2006-03       Impact factor: 3.428

10.  ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells.

Authors:  Juan Wang; Jun-Ying Zhou; Gen Sheng Wu
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

View more
  54 in total

1.  Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer.

Authors:  Jun Okamura; Yiping Huang; David Moon; Mariana Brait; Xiaofei Chang; Myoung Sook Kim
Journal:  Cancer Biol Ther       Date:  2012-02-01       Impact factor: 4.742

2.  In vitro expansion of U87-MG human glioblastoma cells under hypoxic conditions affects glucose metabolism and subsequent in vivo growth.

Authors:  L Lemaire; F Franconi; B Siegler; C Legendre; E Garcion
Journal:  Tumour Biol       Date:  2015-05-02

3.  The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation.

Authors:  George J Cerniglia; Souvik Dey; Shannon M Gallagher-Colombo; Natalie A Daurio; Stephen Tuttle; Theresa M Busch; Alexander Lin; Ramon Sun; Tatiana V Esipova; Sergei A Vinogradov; Nicholas Denko; Constantinos Koumenis; Amit Maity
Journal:  Mol Cancer Ther       Date:  2015-05-20       Impact factor: 6.261

Review 4.  Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer?

Authors:  Chen-Ting Lee; Thomas Mace; Elizabeth A Repasky
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 5.  Theory, instrumentation, and applications of electron paramagnetic resonance oximetry.

Authors:  Rizwan Ahmad; Periannan Kuppusamy
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

6.  Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells.

Authors:  Xuejiao Zhao; Yong Fang; Yang Yang; Yu Qin; Peng Wu; Ting Wang; Huiling Lai; Li Meng; Daowen Wang; Zhihui Zheng; Xinhua Lu; Hua Zhang; Qinglei Gao; Jianfeng Zhou; Ding Ma
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

7.  Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.

Authors:  Selin Oncul; Paola Amero; Cristian Rodriguez-Aguayo; George A Calin; Anil K Sood; Gabriel Lopez-Berestein
Journal:  RNA Biol       Date:  2019-12-17       Impact factor: 4.652

8.  The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Authors:  F F Blanco; M Jimbo; J Wulfkuhle; I Gallagher; J Deng; L Enyenihi; N Meisner-Kober; E Londin; I Rigoutsos; J A Sawicki; M V Risbud; A K Witkiewicz; P A McCue; W Jiang; H Rui; C J Yeo; E Petricoin; J M Winter; J R Brody
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

9.  EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.

Authors:  Alison Roos; Harshil D Dhruv; Sen Peng; Landon J Inge; Serdar Tuncali; Michael Pineda; Nghia Millard; Zachary Mayo; Jennifer M Eschbacher; Joseph C Loftus; Jeffrey A Winkles; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2018-05-03       Impact factor: 5.852

10.  STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells.

Authors:  M R Pawlus; L Wang; C-J Hu
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.